Evidence map›Paper›PMID 39404356›Full record

ArticlemBio2024

The riboflavin biosynthetic pathway as a novel target for antifungal drugs against

Jana Nysten, Arne Peetermans, Dries Vaneynde, Stef Jacobs, Liesbeth Demuyser, Patrick Van Dijck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jana NystenLaboratory of Molecular Cell Biology, Department of Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium.ORCID 0000-0001-5591-0595
Arne PeetermansLaboratory of Molecular Cell Biology, Department of Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium.
Dries VaneyndeLaboratory of Molecular Cell Biology, Department of Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium.
Stef JacobsLaboratory of Molecular Cell Biology, Department of Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium.
Liesbeth DemuyserLaboratory of Molecular Cell Biology, Department of Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium.
Patrick Van DijckLaboratory of Molecular Cell Biology, Department of Biology, Institute of Botany and Microbiology, KU Leuven, Leuven, Belgium.ORCID 0000-0002-1542-897X

Funding

Fonds Wetenschappelijk Onderzoek (FWO) 11PRR24NFonds Wetenschappelijk Onderzoek (FWO) 1S18121NFonds Wetenschappelijk Onderzoek (FWO) 1S19219NOnderzoeksraad, KU Leuven (Research Council, KU Leuven) C14/22/075
6 · The paper itself

Abstract

In recent decades, there has been an increase in the occurrence of fungal infections; yet, the arsenal of drugs available to fight invasive infections remains very limited. The development of new antifungal agents is hindered by the restricted number of molecular targets that can be exploited, given the shared eukaryotic nature of fungi and their hosts which often leads to host toxicity. In this paper, we examine the riboflavin biosynthetic pathway as a potential novel drug target. Riboflavin is an essential nutrient for all living organisms. Its biosynthetic pathway does not exist in humans, who obtain riboflavin through their diet. Our findings demonstrate that all enzymes in the pathway are essential for IMPORTANCE:

Indexed as

Antifungal AgentsBiosynthetic PathwaysCandida albicansCandida glabrataCandidiasisRiboflavinSaccharomyces cerevisiaeAnimalsDisease Models, AnimalFungal ProteinsMiceVirulenceAntifungal AgentsFungal ProteinsRiboflavinantifungalCandidadrug targetsriboflavintransportervitamin B2

Identifiers

PMID39404356
PMCPMC11559065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.